AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05365867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCAN Group
Description: See description in iCAN study arm.
Study NCT05870293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse coaching
Description: 2 sessions of nurse coaching including the Walt Disney method will be applied to the participants.
Study NCT05705414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valine
Description: A medical food intended for use under medical supervision
Study NCT05705414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EEA
Description: A medical food intended for use under medical supervision
Study NCT05950958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal therapy for prevention of delirium
Description: Multimodal therapy for prevention of delirium
Study NCT06160908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NirsCure
Description: True near-infrared light； Once a day, once for 30 minutes, 6 times a week
Study NCT06160908 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham NirsCure
Description: Non near-infrared light irradiation；only the equipment appearance is consistent with the test device；Once a day, once for 30 minutes, 6 times a week
Study NCT05539716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP Therapy
Description: Auto-PAP device (ResMed AirsenseTM Autoset) with a heated humidifier will be provided along with an appropriate mask and connecting hose for nightly use
Study NCT05539716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling Intervention
Description: Lifestyle intervention will include counseling on (a) education on nutrition and exercise; and (b) behavioral support for identifying lifestyle change strategies and problem-solving barriers to improve the regularity and duration of sleep. This will be conducted using brochures on weight loss and sleep hygiene
Study NCT05558124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Fixed dose of Vyxeos (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) (Day 1, 3, and 5) in combination with various dose schedules of Gemtuzumab Ozogamicin (GO)
Study NCT05558124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Participants will be treated at the following dose levels:~Dose Level 1 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 Dose Level 2 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 and 4 Dose Level 3 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1, 4, 7
Study NCT06628908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suzetrigine
Description: Tablets for oral administration.
Study NCT06628908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Capsules for oral administration.
Study NCT06628908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to SUZ)
Description: Placebo matched to SUZ for oral administration.
Study NCT06628908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to SUZ)
Description: Placebo matched to SUZ for oral administration.
Study NCT06628908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to Pregabalin)
Description: Placebo matched to Pregabalin for oral administration.
Study NCT06628908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to Pregabalin)
Description: Placebo matched to Pregabalin for oral administration.
Study NCT05225337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted feeding (TRF)
Description: 8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
Study NCT05225337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily calorie restriction
Description: 25% energy restriction every day Diet counseling provided
Study NCT04966741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: SC injection once daily.
Study NCT06399198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: After adequate local anesthesia is achieved, a horizontal incision will be placed at mucogingival junction level to prepare the recipient bed. A split-thickness flap will be raised without disturbing the periosteum. A free gingival graft will be obtained from the palate. The graft will be shaped and sutured to the recipient surface.
Study NCT04967612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual implantation
Description: Temporary placement of virtual optical lens in the crystalline lens plane.
Study NCT05366075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1 (simple exercise program)
Description: Up to four sessions per day (total duration 20-30 minutes/day). Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week). At discharge, the participants will be encouraged to continue with the exercise program at home.
Study NCT05366075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 2 (comprehensive exercise program)
Description: Two daily sessions (morning and afternoon) of 20 minutes' duration each. Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week).
Study NCT04856202 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advance Care Planning interview
Description: The facilitator will clarify the patients' preferences, asking specific questions regarding personal goals, including religious and cultural beliefs. The facilitator will discuss life supporting treatments that might be applicable to the patient and encourage the patient to weigh up personal benefits and burdens. Treatments may include: invasive therapy (such as chemotherapy or dialysis), hospitalization, resuscitation, ventilation, artificial nutrition or hydration and administration of antibiotics. The patient will also be encouraged to identify specific situations that are likely to improve or diminish his or her quality of life. The facilitator will assist the patient in documenting their wishes, including the assignment of a health care proxy.
Study NCT04654468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg). Dosing schedule will be as described above.
Study NCT05570253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.
Study NCT05570253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.
Study NCT05570253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDX-7320
Description: SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis
Study NCT05570253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05113095 — intervention group
Intervention type: BIOLOGICAL
Intervention: Darvadstrocel
Description: Darvadstrocel injection
Study NCT05354947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Delivery
Description: A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to both, the portal region of the liver and the superior mesenteric plexus.
Study NCT04743505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101
Description: -Provided by Apollomics
Study NCT04743505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: -Given standard of care
Study NCT04872218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: 24 week treatment of IV abatacept following recommended dosages from the monograph
Study NCT04872218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 week treatment of IV placebo following recommended dosages from the abatacept monograph
Study NCT04872218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Description: Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.
Study NCT04872218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Peanut oral immunotherapy
Description: Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.
Study NCT05028738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS will employ the MagPro X100 stimulator equipped with the cool-B70 coil (MagVenture, Farum, Denmark). The dose will be a 120% resting motor threshold (rMT) in accordance to our latest trial using iTBS. Localization of the right and left DLPFC will follow the well-established Beam F3 procedure. Subjects will then undergo 30 sessions of rTMS, once daily on weekdays for 6 weeks. FDA-approved iTBS protocol will consist of bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total, 2 s on, 8 s off, for 3 min 9 sec, at 120% rMT. LFR will consist of 1 Hz stimulation consisting of a single train of 10min duration for 600 pulses total at 120% rMT.
Study NCT06193486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSGV1-PSCA-8T28Z
Description: Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.
Study NCT06193486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an antimetabolite given prior to lymphodepletion.
Study NCT06193486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
Study NCT05981391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional MRI
Description: We will acquire BOLD fMRI images in an unstimulated state using an extended time-series (300 whole-brain volumes over \~ 60-75 min). These data are a main outcome. Data will be processed on an ongoing basis to ensure integrity, and includes controlling for white matter, cerebral spinal fluid, and movement.
Study NCT05981391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinician Administered PTSD Scale for the DSM-5 (CAPS-5)
Description: The CAPS-5 is a semi-structured interview, conducted by an independent evaluator, that measures DSM-5 symptoms of PTSD. Presence of at least one intrusion symptom, one avoidance symptom, two cognition and mood symptoms, and two arousal symptoms for 1 month or more are required to reach the diagnostic threshold.
Study NCT06336746 — intervention group
Intervention type: DEVICE
Intervention: Esophageal Doppler
Description: Esophageal Doppler: measuring cardiac performance. INVOS: measuring regional saturation of the brain.
Study NCT06184477 — intervention group
Intervention type: OTHER
Intervention: PEDIATRIC TONSILLECTOMY; SURGICAL EXPERIENCE AND PROLONGED HOSPITALIZATION
Description: we aim to compare hospitalization times of pediatric patients that operated by expert surgeon or young surgeon
Study NCT06224075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-specific training
Description: Participants in the intervention group will receive the treatment established for the control group and nursing care based on task-specific training. The intervention was designed with the aim of improving inhaler management in COPD patients. The content of the tasks will be adapted to the different types of devices present in the patient's therapeutic regimen, mainly pressurized cartridge and dry powder devices.~In order to carry out the intervention, several tasks related to education, assessment and/or training will be established with the aim of improving the ability to use the prescribed inhalers. The tasks have been classified into 3 blocks: technique execution, device cleaning and medication administration.
Study NCT06224075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: All patients will receive standard treatment during their hospital stay (medical and pharmacological care). This treatment will include steroids, antibiotics, inhaled bronchodilators and oxygen therapy. In addition, during hospitalization they may receive diuretics, anticoagulants and cardiovascular treatments if necessary.
Study NCT06224075 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: All patients will receive standard treatment during their hospital stay (medical and pharmacological care). This treatment will include steroids, antibiotics, inhaled bronchodilators and oxygen therapy. In addition, during hospitalization they may receive diuretics, anticoagulants and cardiovascular treatments if necessary.
Study NCT05210842 — intervention group
Intervention type: OTHER
Intervention: Endoscopy
Description: The procedures are performed using a flexible therapeutic linear array echoendoscope.
Study NCT05981391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tympanometry
Description: Tympanometry will be conducted to assess ear canal volume (cm cubed), maximum pressure (daPa) peak compliance (ml), and type (A, AD, AS, B, B-High, C) for each ear) at 226-Hz admittance.
Study NCT05981391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tinnitus Assessment
Description: Tinnitus acoustic assessment (for tinnitus participants only): Tinnitus ear (left, right, bilateral), pitch matched frequency (Hz) and loudness matched intensity (dB) will be conducted. When available, the tinnitus acoustic assessment only will be repeated at the RII, on the same day and prior to the fMRI scan, to demonstrate reproducibility of results.
Study NCT05981391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Otoscopy
Description: Otoscopy is a clinical procedure used to examine structures of the ear, particularly the external auditory canal, tympanic membrane, and middle ear
Study NCT05727059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Elevate™ System
Description: The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
Study NCT06234397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH3120
Description: BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle
Study NCT06234397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle
Study NCT05932329 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: Dietary Advice provided
Study NCT06228703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula device with flow setting at 40 L/min or higher
Description: Eligible participants will use the high-flow nasal cannula device (Airvo3 or HFT 750) with flow set at 40 L/min or higher
Study NCT05981391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pure tone air and bone-conduction
Description: Pure tone air- and bone-conduction threshold will be conducted to evaluate audiometry and masking levels in both ears, from 250 Hz. To 16000 Hz.
Study NCT05981391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Speech testing
Description: Speech testing will be conducted in both ears, which will include speech reception threshold, speech reception threshold masking level, word recognition presentation level, and word recognition masking level.
Study NCT05981391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Loudness Discomfort
Description: Loudness discomfort levels will be tested in both right and left ears, from 500Hz to 4000Hz and speech reception threshold.
Study NCT05981391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quick Speech in Noise Test
Description: Quick Speech in Noise Test (QuickSIN) is a quick method for clinicians to quantify a patient's ability to hear in noise (1 minute).
Study NCT05981391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Distortion-Product Otoacoustic Emissions (DPOAE)
Description: Distortion-Product Otoacoustic Emissions (DPOAE) is an automated evaluation of cochlear function. A sensitive microphone is placed in the ear canal via a probe assembly with a disposable ear-tip attached to perform and record the measurements. DPOAEs will be elicited at multiple frequencies in both ears (10 min).
Study NCT06213545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In-clinic interpretation
Description: Reading patch test result at clinic
Study NCT06213545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Photo interpretation
Description: Reading patch test result by sending photo to clinic
Study NCT04852783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Neurovascular System
Description: Endovascular embolization of wide-necked, bifurcated saccular intracranial aneurysms.
Study NCT04767282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fruit and Vegetable Prescription
Description: $15 voucher for fruit and vegetables
Study NCT05526989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: 300 mg Dostarlimb will be administered by IV, increasing to 1000 mg after cycle 4.
Study NCT05526989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 200 mg Niraparib will be taken once daily by mouth days 1-21 of all cycles.
Study NCT05788796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Band-aid application
Description: Before starting the study, cotton and band-aids will be provided to the women in the application group by the researchers.~• Pregnant women in the application group will be asked to take a hazelnut-sized cotton ball before going to bed, put it in the middle of the navel and close it diagonally with a band-aid.
Study NCT05295680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hymecromone
Description: Hymecromone 400 mg 3 times daily by mouth.
Study NCT05617209 — intervention group
Intervention type: OTHER
Intervention: thrombin generation measurement
Description: Thrombin generation will be measured in Platelets rich plasma induced either by 1 pM TF or 10 pM TF concentration in presence of different aTFPIAb concentrations (0; 0.5 µg/ml; 0.75 µg/ml; 1.0 µg/ml; 2.0 µg/ml; 4.0 µg/ml)
Study NCT05338151 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Negotiated Interview (BNI)
Description: Brief Negotiated Interview (with referral and telephone booster) alone
Study NCT05338151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BNI+facilitated provision of MAUD
Description: Brief Negotiated Interview (BNI)+ Medication for Alcohol Use Disorder (MAUD)
Study NCT05338151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT
Description: Brief Negotiated Interview (BNI)+Medication for Alcohol Use Disorder (MAUD)+Computer Based Treatment for Cognitive Behavioral Treatment (CBT4CBT)
Study NCT05325034 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Intervention
Description: Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s).~The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies.
Study NCT05325034 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Early Intervention
Description: Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s).~The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies.
Study NCT05575141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: incisional hernia repair
Description: Incisional hernia repair for the treatment of wide ventral incisional hernias.
Study NCT05896748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir - Injectable Suspension (CAB LA)
Description: It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.